Opinions
Paul Harris, CFA
Teva Pharmaceutical
TEVA-N
BUY
Jan 16, 2017
$33.970
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
DON'T BUY
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
biotechnology
pharmaceutical
HOLD
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
biotechnology
pharmaceutical
DON'T BUY
An interesting story. A great Buy at these levels. Trading at about 8X earnings with a nice dividend yield of almost 4%. The largest generic maker globally. They acquired Allergan’s generic business and there are a lot of costs they can take out. Sometimes generics are focused on one drug, but this company is much more diversified across a wide spectrum of pharmaceutical lines. The market is slightly worried about the change of CEOs, as well as a couple of drugs that need to have a new molecule made. Although a generic maker, they also have a pipeline of branded drugs. In the long run, this company will do very, very well.